List of Cresemba drug patents

Cresemba is owned by Astellas.

Cresemba contains Isavuconazonium Sulfate.

Cresemba has a total of 4 drug patents out of which 0 drug patents have expired.

Cresemba was authorised for market use on 06 March, 2015.

Cresemba is available in capsule;oral dosage forms.

Drug patent challenges can be filed against Cresemba from March, 2026.

The generics of Cresemba are possible to be released after 14 September, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6812238 ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
Oct, 2025

(2 years from now)

US10812238 ASTELLAS Configurable reference signals
Oct, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206879 ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof
Sep, 2027

(4 years from now)

US10603280 ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof
Sep, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 6, 2020
Orphan Drug Exclusivity (ODE) Mar 6, 2022
Generating Antibiotic Incentives Now (GAIN) Mar 6, 2027

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: March, 2026

Market Authorisation Date: 06 March, 2015

Treatment: NA


More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in